Article 29(4) Referral in EU Medicines Regulation: Legal Basis, Procedure and Regulatory Decision-Making

Article 29(4) Referral in EU Medicines Regulation: Legal Basis, Procedure and Regulatory Decision-Making
- Introduction
Article structure
References
Regulatory Note

Introduction

The European Union medicines regulatory system provides several mechanisms for resolving disagreements between national competent authorities.

Article 29(4) of Directive 2001/83/EC is one of the more specific of these mechanisms. It applies when Member States cannot reach agreement during the coordination stage of a mutual recognition procedure (MRP) or decentralised procedure (DCP), and the unresolved disagreement is based on a potential serious risk to public health.

The provision therefore belongs to the architecture of national marketing authorisation procedures rather than to the centralised marketing authorisation procedure.

An Article 29(4) referral does not begin because EMA has independently identified a safety issue. It begins with a disagreement between Member States participating in an MRP or DCP. The disagreement is first considered through the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh). If the Member States cannot reach agreement within that process, the reference Member State (RMS) refers the matter to the European Medicines Agency (EMA), where the Committee for Medicinal Products for Human Use (CHMP) conducts the Union-level scientific assessment.

The procedure can be represented as:

MRP or DCP
     |
     v
RMS assessment
     |
     v
CMS review
     |
     v
Potential serious risk
to public health raised
     |
     v
CMDh coordination
     |
     | agreement
     |--------------------> MRP/DCP proceeds
     |
     | no agreement
     v
Article 29(4) referral
     |
     v
EMA / CHMP
     |
     v
Scientific assessment
     |
     v
CHMP opinion
     |
     v
Re-examination, if requested
     |
     v
Final CHMP opinion
     |
     v
European Commission
     |
     v
Binding Union decision
     |
     v
National implementation

Article 29(4) should therefore be understood as an escalation mechanism within the MRP/DCP system. It is not a general-purpose referral procedure and it is not synonymous with an Article 31 pharmacovigilance referral, an Article 30 referral or any of the other Union procedures used for human medicines.

This article examines the procedure from that perspective: first the legal setting and threshold, then the transition from MRP/DCP disagreement to referral, followed by the CHMP assessment, re-examination and European Commission decision.

Article structure

This article is being developed as a single regulatory chapter. The sections below define the complete planned structure; subsequent revisions will develop each section rather than creating additional short sections merely to increase article length.

Introduction
Article 29(4) in the EU regulatory framework
The legal basis in Directive 2001/83/EC
Mutual recognition and decentralised procedures
The roles of RMS and CMS
The potential serious risk to public health threshold
What may constitute the disagreement
The initial CMS objection
The CMDh coordination procedure
Resolution within CMDh
Failure to reach agreement
Initiation of the Article 29(4) referral
The referral notification
Scope of the referred medicinal product
The role of EMA
The role of CHMP
Rapporteurs and scientific assessment
Evidence available to CHMP
The CHMP list of questions
MAH and applicant participation
Submission of evidence
Written explanations
Oral explanations
Assessment reports
The CHMP assessment timetable
The CHMP opinion
Possible CHMP outcomes
Product information
Safety disagreements
Efficacy disagreements
Quality disagreements
Existing marketing authorisations
Repeat-use procedures
Withdrawal during the procedure
Re-examination of the CHMP opinion
The 15-day notification period
The 60-day grounds for re-examination
Scope of re-examination
Re-examination assessment
Final CHMP opinion
European Commission decision-making
CHMP opinion versus Commission decision
National implementation
Regulatory consequences for the marketing authorisation
Article 29(4) and product information changes
Article 29(4) and conditions of authorisation
Article 29(4) and suspension or revocation
Article 29(4) and risk-benefit assessment
Article 29(4) and pharmacovigilance
Why a safety concern does not make Article 29(4) a PV referral
Article 29(4) versus Article 20 pharmacovigilance
Article 29(4) versus Article 20 non-pharmacovigilance
Article 29(4) versus Article 30
Article 29(4) versus Article 31 pharmacovigilance
Article 29(4) versus Article 31 non-pharmacovigilance
Article 29(4) versus Article 107i
Regulatory decision tree
Reading an Article 29(4) procedure
Reading the initial notification
Reading the scientific background
Reading the CHMP questions
Reading the MAH response
Reading the rapporteur assessment
Reading the CHMP opinion
Reading the Commission decision
Reconstructing the regulatory chronology
Procedural timelines and clock stops
IRIS and procedural communications
Regulatory submissions and eCTD
Product-information translations
Article 57 implications
Transfer of a marketing authorisation during referral
Withdrawal and termination of the referral
QPPV implications
Pharmacovigilance system implications
Signal-management implications
PSMF implications
RMP implications
PSUR implications
Regulatory governance
Inspection readiness
Common interpretive errors
Practical worked example
A second worked example: safety
A third worked example: quality or efficacy
What Article 29(4) does not mean
Regulatory interpretation principles
Key distinctions
Practical checklist
Conclusion

1. Article 29(4) in the EU Regulatory Framework

Article 29(4) must be understood in the context of the national authorisation procedures established under EU medicines legislation.

The MRP and DCP allow a medicinal product to be authorised in more than one Member State through a coordinated assessment. The system depends on the participating national competent authorities reaching a common position.

The RMS leads the assessment. The CMSs review the assessment and participate in the procedure.

The legal framework anticipates that disagreements may occur. It therefore provides a sequence for handling them.

The first question is whether the disagreement can be resolved within the MRP/DCP coordination system. For the type of disagreement relevant to Article 29(4), the matter is considered through CMDh.

Only when the Member States fail to reach agreement on grounds of a potential serious risk to public health does the matter move to the Article 29(4) referral procedure.

2. The Legal Basis in Directive 2001/83/EC

The legal basis for the procedure is Article 29(4) of Directive 2001/83/EC.

Article 29(4) is the point at which an unresolved qualifying disagreement is referred to the Agency. The subsequent Union-level referral procedure is governed by the relevant provisions of the Directive, including Articles 32 to 34.

The provisions should therefore be read as a sequence rather than as isolated rules: the initial disagreement arises in the MRP/DCP framework, is considered through Member State coordination, and only then moves to the Union-level referral procedure.

3. Mutual Recognition and Decentralised Procedures

Article 29(4) cannot be understood without first understanding the procedures from which it arises.

In an MRP, a medicinal product already has a marketing authorisation in one Member State and that assessment is used as the basis for recognition in additional Member States. The Member State leading the procedure is the RMS; the participating recognition states are CMSs.

In a DCP, the applicant seeks authorisation in several Member States where the product does not yet have a marketing authorisation. The RMS leads the common assessment and the CMSs review it.

The important common feature for Article 29(4) is that both procedures depend upon agreement among participating Member States.

4. The Roles of the RMS and CMS

The RMS leads the assessment and prepares the assessment report. The CMSs examine that assessment and participate in the regulatory evaluation.

A CMS may disagree with the RMS assessment. Disagreement alone, however, does not create an Article 29(4) referral. The statutory conditions must be met, including the potential serious risk to public health basis for the unresolved disagreement.

The CMS concern therefore needs to identify the scientific or regulatory basis of the disagreement rather than simply record a difference of opinion.

5. The Potential Serious Risk to Public Health Threshold

The concept of a potential serious risk to public health (PSRPH) is central to Article 29(4).

It is a statutory threshold, not a general synonym for uncertainty or scientific disagreement. The fact that an authority has questions about an assessment does not by itself establish that the Article 29(4) threshold has been met.

The European Commission's guidance on the definition of potential serious risk to public health should therefore be considered when assessing whether a particular disagreement falls within Article 29.

The relevant question is whether the concern falls within the regulatory concept of a potential serious risk to public health, not merely whether the evidence is incomplete or contested.

6. What Can the Disagreement Concern?

Article 29(4) is broader than a pharmacovigilance referral. The disagreement may concern efficacy, safety, quality or proposed product information where the statutory public-health threshold is engaged.

A safety concern may therefore form the basis of an Article 29(4) referral, but the legal identity of the procedure remains Article 29(4) because its origin is an unresolved MRP/DCP disagreement. Conversely, a quality concern does not automatically become an Article 20 non-pharmacovigilance procedure merely because quality is involved.

The same scientific subject can therefore arise in different regulatory procedures depending on how the regulatory issue originated.

7. The Initial CMS Objection

The process begins with a CMS identifying a concern during the MRP or DCP. The CMS communicates its disagreement and explains the grounds for the concern.

The objection should identify the substantive regulatory issue rather than merely state that the RMS assessment is considered incorrect. Depending on the case, the disagreement may concern interpretation of clinical evidence, adequacy of efficacy data, safety findings, quality evidence, or proposed product information.

The objection is therefore the beginning of a documented regulatory disagreement. It is not yet the Article 29(4) referral itself.

8. The CMDh Coordination Procedure

A qualifying disagreement is first considered through the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh).

The purpose of this stage is resolution. The Member States have an opportunity to examine the concern, exchange scientific and regulatory reasoning and determine whether a common position can be reached without escalation to the Union level.

Article 29(4) therefore does not replace the MRP/DCP coordination system. It is the escalation mechanism used when the coordination process fails to resolve a qualifying disagreement.

9. Resolution Within CMDh

If the Member States reach agreement during the CMDh coordination stage, the matter does not proceed to Article 29(4). The agreed position is implemented within the MRP/DCP framework.

The existence of a disagreement therefore does not mean that a referral will necessarily occur. A product can generate substantial scientific discussion during an MRP or DCP without becoming the subject of an Article 29(4) procedure.

Conversely, an Article 29(4) entry in the regulatory record indicates that the disagreement survived the coordination stage and required Union-level assessment.

10. Failure to Reach Agreement

Where the Member States cannot reach agreement during CMDh on grounds of a potential serious risk to public health, the matter proceeds to Article 29(4).

The RMS then refers the matter to the Agency. The referral notification contains a detailed statement of the matter or matters on which the Member States disagree and the reasons for the disagreement on potential serious risk to public health grounds.

The notification is therefore the bridge between the national coordination procedure and the Union-level assessment. It should make clear what the RMS concluded, what the CMS considers unacceptable, why the concern meets the relevant threshold and which scientific or regulatory issues remain unresolved.

11. Initiation of the Article 29(4) Referral

The Article 29(4) referral is initiated by the reference Member State after the coordination stage has failed to resolve the qualifying disagreement.

This is an important distinction from procedures in which a Union institution directly initiates a referral. The RMS performs the formal referral function within the Article 29(4) architecture.

The sequence is:

RMS assessment
      |
      v
CMS raises PSRPH concern
      |
      v
CMDh coordination
      |
      v
No agreement
      |
      v
RMS referral
      |
      v
EMA / CHMP

12. The Referral Notification

The referral notification provides the formal description of the unresolved matter. It identifies the issues on which the Member States disagree and explains the reasons for the disagreement.

When reading an actual procedure, the notification should be treated as a primary regulatory document. A useful analysis asks:

What did the RMS conclude?
Which CMS raised the concern?
What precisely does the CMS dispute?
Why is the concern considered a potential serious risk to public health?
Which elements of the assessment or proposed product information are contested?
What question is CHMP ultimately being asked to resolve?

These questions establish the regulatory problem before the reader moves to the CHMP assessment.

13. Scope of the Referred Medicinal Product

The scope of an ordinary Article 29(4) referral is tied to the medicinal product concerned in the MRP or DCP. The scope should be established from the individual procedure rather than inferred from the active substance alone.

This matters where a product has several strengths, pharmaceutical forms, routes of administration, invented names or presentations.

The applicant or MAH should therefore establish the precise medicinal products and presentations within the procedure and maintain that scope consistently across regulatory submissions and internal governance records.

14. The Role of EMA

Once the matter has been referred, EMA provides the administrative and procedural framework for the Union-level assessment.

The scientific assessment itself is performed by CHMP. This distinction between Agency administration and committee scientific decision-making is important: EMA manages the procedure and associated communications, while CHMP assesses the referred scientific and regulatory questions and adopts the opinion.

The applicant or MAH should maintain accurate procedural contacts and ensure that regulatory correspondence received through the applicable EMA systems is routed promptly to the responsible regulatory and scientific functions.

15. The Role of CHMP

The Committee for Medicinal Products for Human Use (CHMP) conducts the Union-level scientific assessment of the Article 29(4) referral.

CHMP examines the issues referred from the MRP/DCP process. It can consider information already submitted to the national competent authorities and, where necessary, request additional information from the applicant or MAH.

CHMP appoints rapporteurs to assess the matter and can draw on additional scientific expertise where appropriate.

The committee is not merely deciding which Member State was correct. It must reach a scientific and regulatory conclusion on the matter referred to it. The Article 29(4) procedure therefore converts a national-authority disagreement into a Union-level assessment.

16. Article 29(4) Is Not a PRAC Procedure

Article 29(4) should not be confused with a pharmacovigilance referral in which PRAC has the central scientific assessment role.

A safety concern can be raised during an Article 29(4) procedure, but the procedure does not become a PRAC referral merely because the subject matter involves safety. Its legal origin remains the unresolved disagreement within an MRP or DCP.

The committee structure is consequently informative. Article 29(4) follows the MRP/DCP → CMDh → CHMP architecture, whereas a pharmacovigilance referral follows the legal route applicable to that pharmacovigilance procedure and may involve PRAC.

17. The Evidence Available to CHMP

CHMP begins with the information forming part of the MRP/DCP history and the referral documentation. Where necessary, it requests additional information from the applicant or MAH.

The evidence may include the original application dossier, RMS assessment, CMS comments, CMDh documentation, referral notification, additional analyses, relevant scientific literature, updated clinical or quality data, revised product information and responses to CHMP questions.

The purpose is not to reopen every element of the original application indiscriminately. The Union-level assessment is directed to the unresolved questions identified in the referral.

18. The CHMP List of Questions

Where additional information is required, CHMP can adopt a List of Questions (LoQ). The LoQ defines the matters that the applicant or MAH must address.

A strong response should permit a direct chain of traceability:

CHMP question
      |
      v
Applicant / MAH response
      |
      v
Supporting evidence
      |
      v
Rapporteur assessment
      |
      v
CHMP conclusion

The response should therefore be structured around the questions rather than presented as an unrelated general update to the dossier.

19. Applicant and Marketing Authorisation Holder Participation

The applicant or MAH has an important role in supplying evidence during the Article 29(4) assessment.

Once informed of the referral, the applicant or MAH must provide the requested documentation and respond to additional questions within the applicable timetable. Written and, where applicable, oral explanations provide opportunities to address the scientific and regulatory issues under consideration.

The applicant or MAH does not control the assessment. CHMP remains responsible for evaluating the evidence and adopting the opinion. The company's responsibility is to provide an accurate, complete, coherent and scientifically supported response to the referred issues.

20. Article 29(4) Is an Escalation, Not a New Application

An Article 29(4) referral should not be understood as a completely new marketing authorisation application submitted to EMA.

It is an escalation of an existing MRP or DCP disagreement. The original assessment remains part of the evidentiary history, while the referral identifies the issues that remain unresolved.

The regulatory record may therefore be distributed across the RMS assessment, CMS comments, CMDh documentation, referral notification, CHMP questions, applicant responses, rapporteur assessments, CHMP opinion and European Commission decision.

A proper regulatory analysis reconstructs this chain rather than reading the final opinion in isolation.

21. The Procedural Architecture at This Stage

At the end of the initial phase, the pathway can be reduced to:

MRP / DCP
     |
     v
RMS assessment
     |
     v
CMS review
     |
     v
PSRPH concern
     |
     v
CMDh coordination
     |
     | agreement
     |--------------------> MRP / DCP continues
     |
     | no agreement
     v
RMS Article 29(4) referral
     |
     v
EMA
     |
     v
CHMP
     |
     v
Questions and/or existing evidence
     |
     v
Scientific assessment

22. Submission of Evidence

The evidence submitted during the Union-level procedure should be organised around the questions referred to CHMP. The applicant or MAH should distinguish information already contained in the MRP/DCP dossier from genuinely new evidence and identify the relevance of new material to the specific regulatory question.

A useful submission structure is:

Element	Purpose
Question	Reproduce the regulatory issue being addressed
Position	State the applicant or MAH conclusion clearly
Evidence	Identify the data supporting that conclusion
Analysis	Explain how the evidence addresses the question
Residual uncertainty	Identify limitations that remain
Proposed regulatory consequence	State the requested conclusion or product-information change

The objective is traceability. A reviewer should be able to move from the CHMP question to the evidence and then to the proposed conclusion without reconstructing the argument from unrelated dossier sections.

23. Written Explanations

Written explanations are a principal means by which the applicant or MAH responds to the scientific issues raised during the referral.

The response should distinguish evidence from interpretation. Where the disagreement concerns a benefit-risk conclusion, the company should explain not only what the data show but why those data support the proposed regulatory position.

The response should also identify any assumptions, uncertainties or limitations. A regulatory submission becomes less persuasive when uncertainty is hidden rather than characterised.

For an inspection-ready regulatory history, the submitted response, supporting analyses, internal review records and final approved version should remain traceable.

24. Oral Explanations

Where the applicable procedure provides an opportunity for oral explanation, the applicant or MAH should use it to clarify the principal unresolved issues rather than attempting to introduce an unstructured second dossier.

The oral explanation should be consistent with the written response. Any material distinction between the written position and the oral presentation should be understood and documented internally.

The regulatory objective is clarification. Oral explanation does not transfer the scientific decision-making function from CHMP to the applicant or MAH.

25. Assessment Reports

The rapporteur assessment is an important part of the Union-level scientific record.

It should be read as an assessment of the evidence against the questions raised by the referral, rather than simply as a restatement of the applicant's position.

For regulatory interpretation, the reader should distinguish three layers:

the evidence supplied by the applicant or MAH;
the rapporteur's scientific interpretation of that evidence;
the final position adopted by CHMP.

These layers are related but are not interchangeable. A company's proposed conclusion is not the same thing as the rapporteur's assessment, and the rapporteur's assessment is not itself the final CHMP opinion.

26. The CHMP Assessment Timetable

The referral operates according to a defined procedural timetable. The applicable timetable should always be checked against the current EMA procedural guidance and the individual procedure because the precise schedule can depend on the procedural stage and on clock stops or additional information requests.

The practical regulatory lesson is that a referral timetable should be managed as a controlled project rather than as a single submission deadline.

A company should maintain, at minimum:

the date of notification;
the date of receipt of each formal document;
the response deadline;
planned internal review dates;
medical and regulatory sign-off dates;
submission date;
any clock-stop period;
the expected committee milestone;
subsequent opinion and implementation dates.

The procedural calendar should be reconciled with the official EMA record rather than maintained solely from internal estimates.

27. The CHMP Opinion

The CHMP opinion is the central scientific conclusion of the Union-level assessment.

It addresses the matters referred to the committee and sets out the regulatory conclusion arising from the assessment.

The opinion should be distinguished from the later European Commission decision. CHMP provides the scientific and regulatory committee opinion; the Commission subsequently adopts the legally binding Union decision within the applicable legal framework.

When analysing an Article 29(4) procedure, the opinion should therefore be read for three purposes:

the conclusion reached by CHMP;
the reasoning supporting that conclusion;
the regulatory consequences proposed for the marketing authorisation and product information.

28. Possible CHMP Outcomes

The precise outcome depends on the subject and evidence of the individual referral. CHMP may conclude that the marketing authorisation can proceed or remain in place subject to defined conditions, or it may conclude that changes are required.

Depending on the legal and scientific circumstances, consequences can include changes to product information, additional risk-control measures, restrictions on use, changes to the conditions of authorisation, or more fundamental regulatory action.

The outcome should therefore be read from the actual CHMP opinion rather than inferred from the fact that an Article 29(4) referral occurred.

A referral is a procedural escalation; it does not predetermine the substantive result.

29. Product Information

Product information is often central to an Article 29(4) disagreement because a scientific disagreement may ultimately concern whether the authorised information adequately reflects the evidence.

The relevant documents may include the Summary of Product Characteristics, package leaflet and labelling, as applicable to the product and procedure.

When product information is amended, the regulatory analysis should distinguish the scientific reason for the change from the implementation wording. The former explains why the regulatory conclusion changed; the latter determines how that conclusion is communicated to healthcare professionals and patients.

The final wording adopted through the regulatory process should be treated as controlled regulatory content and not as a drafting exercise independent of the scientific conclusion.

30. Safety Disagreements

An Article 29(4) referral may involve safety data, including disagreement about whether the available evidence supports a particular safety conclusion or product-information position.

The presence of safety information does not by itself convert the procedure into a pharmacovigilance referral. The procedural origin remains the MRP/DCP disagreement.

For pharmacovigilance professionals, this distinction matters because the safety evidence may nevertheless require review of the broader safety profile, signal information, risk-management measures and benefit-risk assessment. Those activities should support the regulatory response without confusing the legal basis of the referral.

31. Efficacy Disagreements

An Article 29(4) procedure may also arise from disagreement concerning efficacy.

The regulatory question may concern the adequacy, consistency or clinical relevance of evidence supporting the proposed indication or the balance between efficacy and identified risks.

The applicant's response should therefore distinguish statistical findings from clinical interpretation. A numerical result is not, by itself, a regulatory conclusion. CHMP considers the totality of relevant evidence and its implications for the proposed use of the medicinal product.

32. Quality Disagreements

Quality issues can also be relevant to Article 29(4) where the statutory conditions for the procedure are satisfied.

Examples of issues that could become relevant include questions about pharmaceutical quality, manufacturing controls, specifications, stability or the implications of a quality finding for the safe and effective use of the product.

The regulatory route should not be determined solely by the department within the company that owns the data. A CMC issue arising in an MRP/DCP disagreement remains part of the Article 29 framework if the statutory conditions for referral are met.

33. Existing Marketing Authorisations and Repeat-Use Procedures

The regulatory history of a medicinal product may extend beyond the immediate MRP or DCP.

Where a product has previously been authorised through a related national procedure, the effect of the referral on those authorisations must be determined from the specific procedural circumstances and applicable legislation.

Repeat-use procedures require particular care because an earlier MRP outcome can subsequently be used as the basis for recognition in additional Member States. The regulatory record should therefore distinguish the original procedure, later repeat-use activity and the Article 29(4) event itself.

The presence of several national authorisations does not by itself establish that every authorisation is within the scope of a particular referral. Scope must be established from the procedure and its legal basis.

34. Withdrawal During the Procedure

Withdrawal of an application or other change in the applicant's regulatory position does not automatically make the scientific history irrelevant.

Where a referral is affected by withdrawal, the procedural consequences must be determined from the applicable legal framework and the status of the authorisations concerned.

For regulatory governance, the company should document the reason for any withdrawal, the date on which it occurred, the authority informed, the effect on the referral and any remaining obligations. A withdrawal should never be treated internally as a substitute for a documented regulatory conclusion.

35. Re-examination of the CHMP Opinion

The applicant or MAH has a defined opportunity to request re-examination of a CHMP opinion where the applicable legislation and procedure permit it.

Re-examination is not simply an opportunity to repeat the original submission. The request must identify the specific grounds on which the opinion is challenged and should focus the committee's attention on the aspects that the applicant or MAH considers to have been incorrectly assessed or insufficiently considered.

The procedural requirements and deadlines are strict. The current EMA guidance for the applicable referral should always be consulted when a re-examination is contemplated.

The regulatory sequence is:

Initial CHMP assessment
        |
        v
   CHMP opinion
        |
        v
Re-examination request
   where permitted
        |
        v
Re-examination assessment
        |
        v
Final CHMP opinion
        |
        v
European Commission decision

The next chunk will examine the re-examination mechanics in detail, followed by the European Commission decision, national implementation and the comparison of Article 29(4) with the other principal EU referral procedures.

36. The 15-Day Notification Period for Re-examination

The opportunity to seek re-examination begins with a short procedural window. Following receipt of the CHMP opinion, the applicant or marketing authorisation holder has 15 calendar days to notify the Agency in writing of its intention to request re-examination. citeturn0search0turn0search1

This first notification is not the detailed re-examination submission. It is the formal indication that the applicant or MAH intends to challenge the opinion through the re-examination mechanism.

The distinction is operationally important because the two stages have different deadlines. Missing the initial 15-day notification deadline can prevent the subsequent detailed grounds from being considered.

A company contemplating re-examination should therefore establish the decision process before the CHMP opinion is adopted. The regulatory, medical, legal and senior governance functions should know who has authority to decide whether re-examination will be requested and how that decision will be communicated to EMA.

37. The 60-Day Deadline for the Detailed Grounds

Where the intention to seek re-examination has been notified within the applicable period, the detailed grounds for re-examination must be submitted within 60 calendar days of receipt of the CHMP opinion. citeturn0search0turn0search25

The detailed grounds define the substance of the re-examination request. They should identify the aspects of the CHMP opinion that are being challenged and explain the scientific or regulatory basis for the challenge.

The two deadlines should therefore be managed as separate milestones:

Milestone	Regulatory significance
Receipt of CHMP opinion	Starts the relevant re-examination clock
Within 15 calendar days	Notice of intention to request re-examination
Within 60 calendar days	Detailed grounds for re-examination
Within 60 calendar days after detailed grounds	CHMP final opinion following re-examination

If the applicable deadlines are not respected, the request is considered inadmissible and the opinion becomes final for transmission to the European Commission. citeturn0search0

These are therefore not internal target dates. They are statutory procedural deadlines and should be controlled against the official date of receipt.

38. The Scope of Re-examination

Re-examination is limited by the grounds submitted by the applicant or MAH.

The detailed grounds determine which aspects of the CHMP opinion are brought back before the committee. The request may concern all relevant aspects of the opinion or only particular conclusions. citeturn0search0

This has an important drafting consequence: the re-examination document should be constructed around the specific conclusions that are challenged.

A broad assertion that the CHMP reached the wrong conclusion is less useful than a structured demonstration of where the applicant considers the assessment to have gone wrong.

A strong regulatory structure is:

CHMP conclusion
      |
      v
Specific aspect challenged
      |
      v
Scientific or regulatory ground
      |
      v
Evidence already available
      |
      v
Applicant's interpretation
      |
      v
Requested reconsideration

The objective is not to reproduce the entire referral dossier. It is to identify the precise grounds on which the final committee assessment should be reconsidered.

39. No New Data at Re-examination

The re-examination stage has an important evidentiary limitation: the applicant or MAH cannot use the process simply to introduce new data that were not available to CHMP when it adopted the initial opinion. EMA's current guidance expressly states that no new data can be presented at this stage. citeturn0search0turn0search4

This changes how the re-examination strategy should be developed.

The scientific case should focus on the evidence that was already before the committee and on whether that evidence was correctly interpreted, weighted or applied to the regulatory question.

Internally, the company should therefore preserve the evidence base underlying the initial response and be able to reconstruct exactly which analyses and documents were available to CHMP at the time of the original opinion.

40. Re-examination Rapporteurs and Scientific Assessment

New co-rapporteurs are appointed for the re-examination. Their role is to assess the detailed grounds and prepare the scientific basis for the committee's reconsideration. EMA's current procedural guidance indicates that CHMP concludes the re-examination within 60 calendar days of receipt of the detailed grounds. citeturn0search0

The use of new rapporteurs provides an additional layer of independent scientific review. It does not mean that the original assessment is discarded. Rather, the committee reassesses the challenged aspects using the grounds submitted by the applicant or MAH.

The indicative timetable published by EMA includes circulation of the rapporteur assessment reports around Day 30, written comments from CHMP members around Day 40 and discussion and adoption of the final opinion around Day 60. These dates are procedural guidance and should be checked against the timetable for the individual procedure. citeturn0search0

41. Scientific Advisory Group or Expert Consultation

An applicant or MAH may request consultation of a Scientific Advisory Group (SAG) or an ad-hoc expert group during re-examination where appropriate.

EMA's guidance indicates that such a request should be made as early as possible and no later than submission of the detailed grounds for re-examination. citeturn0search0turn0search4

The possibility is particularly relevant where the disputed issue requires specialist scientific expertise that would materially assist the committee's reconsideration.

The request should therefore be justified by the scientific question, not simply by the seriousness of the regulatory outcome.

42. Final CHMP Opinion After Re-examination

The re-examination produces a final CHMP opinion.

That final opinion is the conclusion that proceeds to the European Commission for the subsequent decision-making process. EMA's current guidance states that the final opinion following re-examination is sent to the Commission. citeturn0search0

The final opinion should therefore be distinguished from the initial opinion in the regulatory history.

A useful regulatory chronology is:

Initial CHMP opinion
       |
       v
Re-examination requested?
   /            \
 no              yes
 |                |
 v                v

Opinion Detailed grounds becomes | final v Re-examination | v Final CHMP opinion | v European Commission

Where the request for re-examination is withdrawn, EMA states that the initial CHMP opinion immediately becomes the final opinion. citeturn0search0

43. From CHMP Opinion to European Commission Decision

Once the CHMP opinion is final, the procedure moves from scientific committee assessment into the European Commission decision-making process.

EMA, together with the MAH or applicant and the national competent authorities, finalises the relevant translations and transmits the documentation to the Commission. The Commission then initiates the process leading to a binding decision addressed to the Member States and notified to the MAH or applicant. citeturn0search0

This transition is important because the CHMP opinion and Commission decision have different legal functions.

The CHMP opinion is the committee's scientific and regulatory conclusion.

The Commission decision is the legally binding Union act implementing the outcome within the applicable framework.

The company should therefore continue to track the procedure after CHMP adoption. A CHMP opinion is not the endpoint of the regulatory process.

44. CHMP Opinion Versus Commission Decision

The distinction between opinion and decision is fundamental to reading EU referral records.

Document	Function
CHMP opinion	Scientific and regulatory committee conclusion
Final CHMP opinion after re-examination	Definitive committee conclusion following any permitted re-examination
Commission draft decision	Proposed Union decision prepared within the Commission process
Commission decision	Binding Union decision implementing the regulatory outcome
National implementation	Measures taken by Member States to give effect to the decision for nationally authorised products

The Commission generally takes the CHMP opinion into account when preparing the decision. The legal framework also provides for a process where the Commission's draft decision may, exceptionally, differ from the Agency's opinion, with reasons for the differences. citeturn0search1

For regulatory interpretation, it is therefore incorrect to treat every CHMP opinion as though it were itself the final legally binding instrument.

45. National Implementation of the Commission Decision

Article 29(4) concerns medicinal products authorised through national procedures, including MRP and DCP products. Consequently, implementation of the Union decision has a national-authorisation component.

Following the Commission decision, the relevant national competent authorities and the MAH implement the outcome in accordance with the applicable EU and national procedural framework. EMA's current guidance points to CMDh recommendations for implementation of Commission decisions concerning nationally authorised products. citeturn0search0

Implementation can involve:

amendment of national marketing authorisation information;
harmonisation of product information;
implementation of conditions or restrictions;
suspension or revocation where required;
completion of translations and national steps;
associated regulatory submissions and records.

The exact implementation route depends on the Commission decision and the nature of the regulatory outcome.

46. Regulatory Consequences for the Marketing Authorisation

An Article 29(4) procedure does not have a predetermined outcome.

The current EMA guidance identifies several possible CHMP outcomes, including a conclusion that the application does not satisfy the criteria for authorisation, amendment of proposed product information, granting of an authorisation subject to conditions, or maintenance, variation, suspension or revocation of already granted marketing authorisations, as applicable. citeturn0search0

The regulatory consequence therefore follows the scientific conclusion rather than the mere fact that a referral was initiated.

This distinction is important for both applicants and existing MAHs. A referral should trigger preparation for multiple possible outcomes, but internal planning should not assume that the procedure necessarily ends in a negative regulatory action.

47. Article 29(4) and Product-Information Changes

Where the CHMP assessment identifies a need to amend product information, the proposed wording becomes part of the regulatory outcome.

The scientific conclusion and the wording should be considered together. A change to a contraindication, warning, adverse-reaction statement, indication, dosing instruction or other section is not merely editorial. It is the regulatory expression of the underlying scientific assessment.

The MAH should therefore maintain traceability between:

Evidence
   |
   v
Scientific conclusion
   |
   v
Regulatory rationale
   |
   v
Proposed wording
   |
   v
Final approved wording
   |
   v
National implementation

This traceability is particularly important where several Member States have different national product-information histories before the referral.

48. Article 29(4) and Conditions of Authorisation

The regulatory framework permits a marketing authorisation to be granted subject to conditions considered essential for the safe and effective use of the medicinal product, including conditions relating to pharmacovigilance. citeturn0search1

A condition attached to an authorisation should therefore not be treated as equivalent to ordinary product-information wording.

Conditions can impose a specific regulatory obligation or restriction that forms part of the authorisation framework.

For an MAH, the implementation plan should identify each condition separately, assign ownership and establish objective evidence that the condition has been fulfilled or is being maintained as required.

Where a condition has pharmacovigilance implications, the PV organisation should be involved in interpreting the requirement and maintaining the associated evidence.

49. Article 29(4) and Suspension or Revocation

In appropriate circumstances, the regulatory outcome can include suspension or revocation of a marketing authorisation. The current EMA Article 29(4) guidance expressly identifies suspension or revocation among the possible outcomes for already granted marketing authorisations. citeturn0search0

These are substantially different outcomes from a product-information amendment.

A suspension temporarily prevents the product from being marketed under the affected authorisation, subject to the terms of the decision. Revocation removes the marketing authorisation.

The practical consequences must therefore be read directly from the Commission decision and its implementation requirements rather than inferred from the scientific opinion alone.

50. Article 29(4) and Benefit-Risk Assessment

Although Article 29(4) can involve safety, efficacy or quality disagreements, the ultimate regulatory question commonly concerns whether the medicinal product can meet the applicable requirements for authorisation and use.

Benefit-risk reasoning may therefore connect evidence from different domains.

For example, a safety concern cannot necessarily be evaluated in isolation from therapeutic benefit. Similarly, a quality concern may become regulatory-significant because of its potential effect on the safety or efficacy of the medicinal product.

A robust analysis should therefore distinguish:

the factual finding;
the scientific interpretation;
the uncertainty surrounding that interpretation;
the clinical consequence;
the regulatory consequence.

This is one reason Article 29(4) should not be reduced to a checklist of procedural dates. The procedure exists to resolve a substantive regulatory disagreement.

51. Article 29(4) and Pharmacovigilance

Pharmacovigilance professionals may become closely involved in an Article 29(4) procedure when the disagreement concerns safety.

Their role may include analysis of individual case safety reports, signal information, epidemiological evidence, literature, exposure estimates, risk-management measures and the overall safety profile.

The involvement of PV does not alter the legal basis of the procedure.

The regulatory origin remains the unresolved MRP/DCP disagreement under Article 29. The PV function supplies scientific and system-level expertise relevant to the safety question.

For the QPPV, this creates an important governance distinction: the QPPV should ensure appropriate oversight of safety information and the pharmacovigilance system, while the regulatory function remains responsible for managing the Article 29 procedure itself and its legal deadlines.

52. Why a Safety Concern Does Not Make Article 29(4) a PV Referral

The subject matter of a regulatory procedure and its legal basis are not the same thing.

An Article 29(4) procedure may involve a safety concern, but its defining feature is that the concern arose from an unresolved disagreement during an MRP or DCP and was escalated under Article 29(4).

By contrast, the central legal architecture of a pharmacovigilance referral depends on the applicable referral provision and the type of marketing authorisation involved.

The distinction can be tested with a simple question:

Where did the regulatory procedure originate?

If the answer is an unresolved MRP/DCP disagreement on potential serious risk to public health, Article 29(4) is the relevant route.

If the answer is a pharmacovigilance concern falling within a specific PV referral provision, a different procedure applies.

This distinction prevents the common analytical error of classifying EU regulatory procedures solely by the scientific topic under discussion.

53. Article 29(4) Versus Article 20

Article 20 and Article 29(4) arise from different regulatory contexts.

Article 20 concerns referrals involving centrally authorised medicinal products and the pharmacovigilance or other regulatory grounds specified in the applicable legislation.

Article 29(4), by contrast, arises from an unresolved disagreement during an MRP or DCP involving a potential serious risk to public health.

The principal distinction is therefore not simply safety versus non-safety. It is the combination of legal basis, authorisation route and procedural origin.

Feature	Article 29(4)	Article 20
Starting point	MRP/DCP disagreement	Applicable Union referral involving CAPs
Key coordination body at origin	CMDh	Depends on referral type; PRAC has a central role for PV referrals
Public-health threshold	Potential serious risk to public health	Determined by the applicable Article 20 provision
Scientific committee	CHMP for Article 29(4)	PRAC and/or CHMP depending on the procedure
Regulatory population	Nationally authorised products in MRP/DCP context	Centrally authorised products

The exact legal pathway should always be verified against the current legislation and procedure-specific guidance.

54. Article 29(4) Versus Article 30

Article 30 addresses a different type of regulatory disagreement within the EU system.

The key issue is the existence of divergent national decisions concerning the same medicinal product and the need to resolve that divergence at Union level.

Article 29(4), by contrast, arises during an MRP or DCP before the coordinated national authorisation process has been successfully completed, where the qualifying disagreement concerns a potential serious risk to public health.

The practical distinction is therefore chronological as well as legal:

Article 29(4)
disagreement during MRP/DCP
        |
        v
   Union referral

Article 30
divergent national positions
        |
        v
   Union referral

The existence of different national regulatory positions is therefore not sufficient, by itself, to classify a procedure as Article 29(4).

55. Article 29(4) Versus Article 31

Article 31 is another major Union referral mechanism, but its legal trigger and procedural architecture differ from Article 29(4).

An Article 31 referral may arise where Union interests are involved and can cover pharmacovigilance and non-pharmacovigilance matters under the applicable provisions.

For pharmacovigilance Article 31 procedures, PRAC plays a central role in the scientific assessment before the matter proceeds through the applicable CHMP or CMDh pathway.

Article 29(4) begins earlier in the national procedure: it is a mechanism for resolving a qualifying disagreement in an MRP or DCP.

This is why the following distinction is useful:

Question	Article 29(4)	Article 31
What triggers the procedure?	Unresolved MRP/DCP disagreement on PSRPH grounds	Applicable Article 31 trigger and Union-interest grounds
Origin	MRP/DCP	Union referral mechanism
Main initial coordination	CMDh	PRAC or CHMP depending on legal basis
Core purpose	Resolve the specific MRP/DCP disagreement	Resolve the Union-level regulatory issue within Article 31 framework

The scientific subject may overlap, but the legal route does not.

56. Article 29(4) Versus Article 107i

Article 107i is specifically associated with urgent Union-level action in the pharmacovigilance framework for nationally authorised medicines.

Its purpose and trigger are therefore different from Article 29(4).

Article 29(4) begins with an MRP/DCP disagreement and a potential serious risk to public health. Article 107i is an urgent pharmacovigilance route with its own statutory conditions and procedural sequence.

For pharmacovigilance professionals, the distinction is particularly important because both procedures can involve serious safety concerns while reaching the EU level through different legal mechanisms.

The correct classification should therefore be based on the legal trigger and procedural origin, not on the severity of the adverse event alone.

The next chunk will move from these legal distinctions to the practical interpretation of an Article 29(4) procedure: how to read the referral documents, reconstruct the regulatory chronology, manage procedural timelines, understand IRIS and submission requirements, and translate the outcome into QPPV and pharmacovigilance system actions.

57. A Regulatory Decision Tree for Article 29(4)

An Article 29(4) procedure is easier to interpret when its legal sequence is separated from the scientific subject matter. The following decision tree provides a practical way of determining whether a regulatory event belongs to the Article 29(4) pathway.

MRP or DCP
    |
    v
Positive RMS assessment
    |
    v
CMS disagrees
    |
    v
Is the disagreement based on a
potential serious risk to public health?
    |
   yes
    v
CMDh coordination
    |
    v
Agreement reached?
   / \
 yes  no
  |    |
  v    v
MRP/DCP  Article 29(4)
continues referral
         |
         v
        EMA
         |
         v
        CHMP
         |
         v
   Scientific assessment
         |
         v
   CHMP opinion
         |
         v
Re-examination requested?
      /       \
    no         yes
     |          |
     v          v
Final CHMP   Re-examination
opinion           |
     |            v
     |       Final CHMP opinion
     |            |
     \____________/
                  |
                  v
        European Commission
                  |
                  v
       National implementation

The value of the decision tree is not that it replaces the legislation. It provides a framework for locating a particular event within the legislation and for avoiding confusion between procedures that may address similar scientific issues.

The most important classification questions are therefore sequential rather than thematic:

Was the issue identified during an MRP or DCP?
Was the RMS assessment positive?
Did one or more CMSs raise a qualifying PSRPH concern?
Did the Member States fail to reach agreement through CMDh?
Was the matter referred by the RMS under Article 29(4)?
Is the subsequent assessment being conducted by CHMP under the Article 29(4) framework?

If these elements are present, the procedure should be analysed as an Article 29(4) referral rather than classified merely by whether the scientific issue concerns safety, efficacy or quality. EMA's current guidance confirms that Article 29(4) applies where Member States fail to reach agreement in the Article 29(1)–(3) coordination procedure on grounds of a potential serious risk to public health. citeturn0search0

58. How to Read an Article 29(4) Procedure

An Article 29(4) procedure should be read chronologically.

The final CHMP opinion is important, but reading it in isolation can obscure why the referral occurred and what question CHMP was actually required to resolve.

A useful reading order is:

Identify the medicinal product and participating Member States.
Establish whether the procedure originated from an MRP or DCP.
Identify the RMS and the objecting CMS or CMSs.
Read the referral notification.
Identify the precise PSRPH concern.
Determine whether the concern concerns efficacy, safety, quality or product information.
Read the CHMP list of questions, if one was adopted.
Examine the applicant or MAH response.
Read the rapporteur and co-rapporteur assessment.
Read the CHMP opinion.
Determine whether re-examination occurred.
Read the final CHMP opinion where applicable.
Read the European Commission decision.
Determine how the decision was implemented nationally.

This sequence reconstructs the regulatory argument rather than simply recording the outcome.

The distinction is particularly important where the final decision appears straightforward but the underlying disagreement was scientifically complex. The referral documents explain the problem; the responses and assessment reports explain how it was evaluated; and the final decision explains the legal consequence.

59. Reading the Initial Referral Notification

The referral notification is the starting point for understanding the Union-level question.

EMA's Article 29(4) guidance states that the RMS provides the notification to CHMP/Agency and that it includes a detailed statement of the matters on which the Member States disagree and the reasons for the disagreement on PSRPH grounds. citeturn0search0

The reader should therefore identify four elements immediately:

Element	Question to answer
Regulatory history	What MRP or DCP produced the disagreement?
Objecting authority	Which CMS raised the concern?
Scientific issue	What evidence or conclusion is disputed?
PSRPH rationale	Why is the concern considered potentially serious for public health?

The notification should be read against the preceding RMS assessment and CMS comments where those documents are available.

This establishes the difference between the original regulatory conclusion and the concern that triggered escalation.

60. Reading the Scientific Background

The scientific background should be reconstructed before attempting to interpret the regulatory conclusion.

For a safety issue, this may require consideration of clinical trials, spontaneous reports, epidemiological studies, literature, biological plausibility, exposure and the existing safety profile.

For an efficacy issue, the relevant evidence may include clinical-trial design, endpoints, statistical analyses, subgroup findings, consistency across studies and clinical relevance.

For a quality issue, the assessment may involve manufacturing, specifications, stability, analytical methods, process controls or the relationship between a quality attribute and product performance.

The important distinction is between the existence of evidence and the regulatory interpretation of that evidence.

An Article 29(4) referral does not necessarily mean that new evidence has suddenly appeared. It may mean that existing evidence has been interpreted differently by the participating authorities.

61. Reading the CHMP Questions

Where CHMP adopts a list of questions, the questions provide the clearest statement of what the committee requires from the applicant or MAH.

The response should therefore be mapped question-by-question.

A useful review table is:

CHMP question	Evidence requested	Applicant conclusion	Rapporteur conclusion	CHMP conclusion
Question 1	Defined evidence	Position	Assessment	Final conclusion
Question 2	Defined evidence	Position	Assessment	Final conclusion
Question 3	Defined evidence	Position	Assessment	Final conclusion

This approach prevents an important regulatory issue from becoming lost within a large scientific submission.

It also makes later inspection and governance review substantially easier because the company can demonstrate how each material regulatory question was addressed.

EMA's current guidance specifies that where a list of questions is adopted, the MAH/applicant's written summary should follow the numbering of the CHMP questions and, where applicable, the list of outstanding issues. citeturn0search0

62. Reading the MAH or Applicant Response

The response should be read as an argument rather than merely as a data package.

For each question, the reviewer should ask:

What conclusion is the company seeking?
What evidence supports it?
Is the evidence directly relevant to the question?
Are there important limitations?
Has contrary evidence been addressed?
Does the proposed regulatory conclusion follow from the evidence?

A high-quality response makes the chain explicit.

Question
   ↓
Regulatory issue
   ↓
Relevant evidence
   ↓
Scientific interpretation
   ↓
Uncertainty
   ↓
Benefit-risk implication
   ↓
Requested regulatory conclusion

This structure is particularly important in a referral because the committee is not assessing the dossier in the same context as the original national assessment. The response must make the relevance of the evidence clear within the referred question.

EMA requires referral responses to be submitted electronically and structured according to the eCTD/CTD format, with a signed cover letter and written summary responding to each question. citeturn0search0

63. Reading the Rapporteur Assessment

The rapporteur assessment is the scientific evaluation of the information available to CHMP.

The reader should distinguish between:

the applicant's factual claims;
the evidence itself;
the rapporteur's interpretation;
areas of agreement;
areas of disagreement;
unresolved uncertainty;
the rapporteur's proposed conclusion.

A useful technique is to annotate each major conclusion as one of three categories:

Evidence: What is directly demonstrated by the available data?

Interpretation: What scientific conclusion is drawn from those data?

Regulatory consequence: What should happen to the marketing authorisation or product information as a result?

This separation reduces the risk of treating an interpretive statement as though it were a direct finding from the underlying data.

EMA confirms that the CHMP co-rapporteurs' assessment reports reflect the data reviewed and considered relevant to the assessment and are circulated to CHMP members for comments. citeturn0search0

64. Reading the CHMP Opinion

The CHMP opinion should be read as the committee's conclusion on the referred matter.

The most important task is to identify the relationship between the scientific reasoning and the regulatory consequence.

A useful extraction framework is:

Question	Interpretation
What did CHMP conclude scientifically?	Core scientific finding
What uncertainty remained?	Residual limitation
What did CHMP conclude about benefit-risk?	Regulatory assessment
What action was recommended?	Regulatory consequence
What product information changed?	Implementation requirement

The opinion should not be interpreted as though every statement has equal regulatory significance. Some sections provide background, while others establish the actual conclusion and recommended action.

The final operative wording should therefore be distinguished from explanatory material.

65. Reading the European Commission Decision

The Commission decision is the document that should be used to establish the legally binding Union outcome.

EMA's current guidance states that after the final CHMP opinion, the Agency works with the MAH and national competent authorities to finalise translations before sending the documentation to the European Commission, which then starts the decision-making process leading to a binding decision addressed to the Member States and notified to the MAH/applicant. citeturn0search0

The decision should therefore be read for:

the legal basis;
the medicinal products concerned;
the operative regulatory outcome;
conditions or restrictions;
required amendments to product information;
implementation requirements;
effective dates;
any provisions concerning suspension, revocation or maintenance.

The Commission decision should be treated as the controlling document for the final legal outcome, subject to the applicable legal framework and subsequent implementation measures.

66. Reconstructing the Regulatory Chronology

For complex referrals, a chronology is often more informative than a narrative summary.

A useful chronology contains at least:

Date	Event	Authority	Regulatory significance
Day 0	MRP/DCP milestone	RMS/CMS	Starting context
Date	CMS concern	CMS	PSRPH issue raised
Date	CMDh discussion	CMDh	Attempted resolution
Date	Referral	RMS/EMA	Article 29(4) initiated
Day 1	CHMP discussion	CHMP	Rapporteurs/questions
Date	MAH response	MAH/Applicant	Evidence submitted
Date	Assessment report	Rapporteurs	Scientific assessment
Date	CHMP opinion	CHMP	Committee conclusion
Date	Re-examination	CHMP	If applicable
Date	Commission decision	EC	Binding Union outcome
Date	National implementation	NCAs/MAH	Local implementation

This chronology should distinguish calendar dates from procedural days.

The two are not interchangeable because a procedure may contain clock stops and because the official starting point depends on the relevant procedural event.

67. Procedural Timelines and Clock Stops

The Article 29(4) procedure has a defined CHMP assessment timetable, but the timetable must be interpreted correctly.

EMA's current guidance describes an Article 29(4) procedure beginning with a list of questions as Day 0 for receipt of the referral notification and relevant documentation, Day 1 for the first CHMP discussion and adoption of the list of questions, a clock stop while the MAH/applicant prepares responses, and Day 60 for adoption of the CHMP opinion after the clock restarts. citeturn0search0

A second pathway exists where CHMP begins by assessing the documentation already available rather than adopting a list of questions. EMA describes this pathway separately, with assessment reports circulated around Day 20 and oral explanations occurring during the assessment phase where applicable. citeturn0search0

The practical implication is that a regulatory tracker should not simply calculate "60 days from referral" and assume that every milestone follows automatically.

The official timetable for the individual procedure should be treated as authoritative.

68. IRIS and Procedural Communications

EMA's current Article 29(4) guidance identifies IRIS as the platform through which the Agency communicates referral documentation to the designated MAH/applicant contact.

The MAH/applicant should designate a contact person and register that person in IRIS before the procedure starts. EMA states that documents made available through IRIS to that contact person constitute effective receipt for purposes including calculation of procedural timelines. citeturn0search0

This makes procedural contact management a regulatory control, not simply an administrative convenience.

The company should therefore maintain:

a named primary contact;
appropriate backup arrangements;
accurate IRIS registration;
clear internal routing of EMA correspondence;
documented receipt dates;
controlled transfer of deadlines into the regulatory tracker.

A missed communication can become a missed regulatory deadline.

69. Regulatory Submissions and eCTD

EMA's current guidance requires referral submissions to be made electronically and describes use of the eSubmission Gateway or eSubmission Web Client with XML delivery files. The response should follow the modular CTD structure, with working documents supplied outside the eCTD structure where required. citeturn0search0

The submission process should therefore be treated as part of the regulatory procedure rather than as a separate technical task.

At minimum, the submission team should control:

procedure number;
submission type;
response numbering;
module placement;
document naming;
working-document requirements;
cover letter;
signed documents;
technical validation;
acknowledgement of receipt.

EMA specifically notes that successful electronic submission generates an acknowledgement of receipt and that, if no acknowledgement is received, the submission should be considered unsuccessful. citeturn0search0

The regulatory significance is straightforward: scientific completeness does not compensate for an unsuccessful submission.

70. Product-Information Translations

Where the CHMP opinion contains amendments to product information, the translation process becomes part of the post-opinion implementation sequence.

EMA's current guidance states that translations of the relevant product information are provided in all EU languages, including Icelandic and Norwegian where applicable. Member State linguistic checks occur after adoption of the opinion, followed by submission of the amended translations and completed QRD form according to the specified timetable. citeturn0search0

The process therefore involves more than translating the English text.

The MAH must maintain control over:

the source wording;
language versions;
Member State linguistic comments;
approved amendments;
QRD documentation;
final submission;
national implementation.

Where a referral changes safety information, the pharmacovigilance organisation should be involved in verifying that the implemented safety wording corresponds to the final regulatory outcome.

71. Article 57 Implications

The Article 29(4) procedure can have implications for the Article 57 database where a marketing authorisation is withdrawn or transferred during the referral.

EMA's current guidance states that where a marketing authorisation or application is withdrawn during the referral, the former MAH/applicant should inform the EMA procedure lead and, for authorised products, update the Article 57 database without delay. For a transfer, both the former and new MAH should update the Article 57 database without delay, and the new MAH should provide the relevant transfer documentation to EMA. citeturn0search0

This illustrates a broader principle: changes in the legal holder of a marketing authorisation do not occur independently of the ongoing referral record.

Regulatory operations should therefore coordinate referral management, Article 57 maintenance and marketing-authorisation transfer activities.

72. Transfer of a Marketing Authorisation During the Referral

A transfer of a marketing authorisation during an Article 29(4) procedure creates a continuity issue for both the regulatory procedure and the underlying authorisation.

The new MAH must be able to assume responsibility for the ongoing regulatory dialogue without losing procedural history.

The handover should therefore include, at minimum:

the referral notification;
the current procedural timetable;
all EMA correspondence;
submissions and acknowledgements;
CHMP questions and responses;
assessment reports received;
product-information versions;
translation status;
pending regulatory actions;
Article 57 status;
the designated EMA procedure contact.

EMA's current guidance states that following receipt of the transfer decision, the Agency informs the former MAH that it is no longer included in the referral in relation to the transferred marketing authorisation. citeturn0search0

The regulatory lesson is that a marketing-authorisation transfer during an active referral should be managed as a controlled transition of procedural responsibility, not simply as an administrative change of ownership.

The next chunk will address Sections 73–90, including withdrawal and termination, QPPV and pharmacovigilance implications, PSMF/RMP/PSUR interfaces, governance and inspection readiness, common interpretive errors, worked examples, the practical checklist, conclusion, references and the final regulatory note.

73. Withdrawal and Termination of the Referral

A referral can end without the full sequence proceeding to a substantive final regulatory outcome. The regulatory record should therefore distinguish withdrawal, termination, closure following agreement, and completion through a final CHMP opinion and Commission decision.

Where an applicant or marketing authorisation holder withdraws its application or otherwise changes the regulatory position during the procedure, the consequences depend on the procedural stage and the legal status of the medicinal product concerned. A withdrawal should not be treated as though the scientific concerns have necessarily been resolved.

For regulatory governance, the important questions are:

what was withdrawn;
by whom;
on what date;
at what procedural stage;
whether the withdrawal affected all Member States concerned;
whether any existing marketing authorisations remained in force;
what regulatory action, if any, followed.

The final procedural status should be established from the official EMA and national regulatory record rather than inferred from a withdrawn application alone.

74. Implications for the QPPV

An Article 29(4) referral can become relevant to the QPPV when the disagreement concerns safety or has consequences for the benefit-risk balance of a medicinal product.

The QPPV's role should not be confused with that of the regulatory lead or the legal owner of the referral procedure. The QPPV remains responsible for the pharmacovigilance system and must have appropriate access to safety information relevant to the benefit-risk evaluation.

Where the referral concerns a safety issue, the QPPV should be able to establish:

what safety information triggered or contributed to the concern;
how the issue was assessed within the pharmacovigilance system;
whether the issue was already known as a signal or identified risk;
whether new information changed the benefit-risk assessment;
what risk-management measures were considered;
how the regulatory conclusion was communicated into the PV system.

The referral therefore provides a useful test of the interface between regulatory affairs and pharmacovigilance governance.

A QPPV should not be expected to own every procedural activity in an Article 29(4) referral. The relevant expectation is that the pharmacovigilance system is appropriately informed, that safety information is evaluated, and that the QPPV has sufficient visibility of decisions affecting the safety profile and benefit-risk balance.

75. Pharmacovigilance System Implications

Where an Article 29(4) referral results in a new or changed safety conclusion, the pharmacovigilance system may need to incorporate that conclusion into its ongoing activities.

The consequences depend on the decision. A revised warning, contraindication or adverse-reaction profile may require corresponding changes to safety monitoring, signal management, medical review, literature surveillance or risk-management activities.

The key principle is traceability.

The organisation should be able to connect the regulatory conclusion with the pharmacovigilance actions that follow it:

Article 29(4) conclusion
        ↓
Safety or benefit-risk implication
        ↓
PV system assessment
        ↓
Required PV action
        ↓
Implementation evidence
        ↓
Ongoing monitoring

This does not mean that every Article 29(4) outcome requires a new signal, a new RMP or a new study. Those conclusions should be based on the actual regulatory decision and the applicable pharmacovigilance requirements.

76. Signal-Management Implications

A safety disagreement raised during an Article 29(4) procedure may concern an existing signal, information that has not yet been formally validated as a signal, or a broader assessment of the safety profile.

The organisation should therefore distinguish the regulatory procedure from its internal signal-management classification.

An Article 29(4) referral does not automatically establish that a validated safety signal exists.

Conversely, a referral concerning a known safety signal should not be treated as though the referral itself constitutes the complete signal assessment.

The signal-management record and the regulatory record should remain linked but conceptually distinct.

Where the referral produces a material change in the understanding of a risk, the organisation should determine whether existing signal-management documentation, safety specifications, risk assessments or governance records require updating.

77. PSMF Implications

The Pharmacovigilance System Master File (PSMF) should provide an accurate description of the pharmacovigilance system and its interfaces with relevant regulatory processes.

An Article 29(4) referral does not automatically require a PSMF revision. The relevant question is whether the referral or its outcome materially changes information that the PSMF is required to describe.

Examples may include changes affecting:

pharmacovigilance responsibilities;
safety-data flows;
risk-management activities;
significant safety processes;
organisational interfaces;
oversight arrangements;
important procedural controls.

The referral itself should therefore be evaluated through the organisation's normal PSMF change-control process rather than treated as an automatic PSMF-change trigger.

Where a PSMF update is required, the organisation should preserve the rationale and effective date of the change.

78. RMP Implications

An Article 29(4) outcome may have consequences for the Risk Management Plan where the final regulatory conclusion identifies a new important risk, changes the characterisation of an existing risk, changes missing information, or requires additional risk-minimisation or pharmacovigilance activity.

The appropriate response depends on the Commission decision and the applicable RMP requirements.

The regulatory conclusion should therefore be translated into the RMP framework deliberately rather than by automatically adding every referral issue to the RMP.

A useful assessment asks:

Has the safety specification changed?
Has an important identified or potential risk changed status?
Has missing information changed?
Has additional pharmacovigilance been required?
Has additional risk minimisation been required?
Has routine risk minimisation changed?
Is an RMP update required by the regulatory outcome?

The answers should be documented and traceable to the final regulatory decision.

79. PSUR Implications

Where the Article 29(4) outcome affects the safety profile, subsequent periodic benefit-risk evaluation should reflect the new regulatory position where relevant.

The PSUR or other applicable periodic safety report should not simply repeat the wording of the Commission decision. The regulatory outcome should be incorporated into the ongoing scientific assessment of the product's benefits and risks.

Depending on the issue, this may affect:

the identified and potential risks considered in the report;
cumulative safety evaluation;
signal evaluation;
effectiveness of risk-minimisation measures;
benefit-risk analysis;
actions taken during the reporting interval.

The regulatory decision therefore becomes part of the product's subsequent safety history.

80. Regulatory Governance

Article 29(4) referrals benefit from clear governance because the procedure crosses organisational boundaries.

A typical governance structure may involve regulatory affairs, medical, pharmacovigilance, clinical development where applicable, quality or CMC, legal and senior management.

The exact structure is organisation-specific. What matters is that responsibilities are unambiguous and that the decision-making chain can be reconstructed after the procedure.

Governance records should establish:

who owned the regulatory procedure;
who assessed the scientific issue;
who approved submissions;
who assessed safety implications;
who authorised responses to CHMP questions;
who approved implementation of the final decision.

The QPPV should have appropriate visibility where the matter affects pharmacovigilance or benefit-risk.

The governance model should also provide for continuity during absences and clearly identify delegated authorities.

81. Inspection Readiness

An Article 29(4) referral can become relevant during regulatory or pharmacovigilance inspection because it provides a concrete example of how the organisation identified, assessed, escalated and implemented a significant regulatory issue.

Inspection readiness should focus on the actual record rather than on a theoretical SOP description.

An inspector should be able to follow a coherent chain from the original concern to the final implemented outcome.

A useful inspection file may contain:

the MRP/DCP assessment;
CMS objections;
CMDh documentation;
referral notification;
EMA procedural correspondence;
CHMP questions;
company responses;
scientific analyses;
rapporteur assessments where available;
CHMP opinion;
re-examination documents, if applicable;
Commission decision;
implementation records;
resulting product-information changes;
relevant PV, RMP or PSMF actions.

The objective is not to create a duplicate dossier for inspection. It is to ensure that the records already maintained across regulatory, quality and PV systems can be retrieved and connected.

82. Common Interpretive Errors

Several errors recur when Article 29(4) procedures are interpreted.

Treating every Article 29 disagreement as a referral

A disagreement during an MRP or DCP does not automatically become an Article 29(4) referral. The statutory conditions and coordination process matter.

Treating Article 29(4) as a pharmacovigilance referral

The presence of a safety issue does not change the legal origin of the procedure.

Treating the CHMP opinion as the Commission decision

The CHMP opinion is the committee's conclusion. The Commission decision is the binding Union act.

Ignoring the CMDh stage

The referral is the endpoint of an unsuccessful Member State coordination process, not the first step.

Reading the final opinion without the original disagreement

The meaning of the CHMP conclusion is often clearer when the original CMS objection and RMS position are reconstructed first.

Assuming every referral produces a negative outcome

Article 29(4) can produce different regulatory outcomes depending on the scientific assessment.

Treating procedural dates as interchangeable

The date of the referral, receipt of the opinion, notification of re-examination and submission of detailed grounds each has a different procedural significance.

83. Practical Worked Example: Efficacy Disagreement

Consider an MRP in which the RMS concludes that the available clinical evidence supports the proposed indication. A CMS disagrees and considers that the evidence does not establish the claimed benefit and raises a potential serious risk to public health.

The matter proceeds through CMDh coordination but the Member States cannot reach agreement.

The RMS refers the matter under Article 29(4).

CHMP then examines the specific question referred to it, including the clinical evidence supporting the indication.

The applicant is asked to address the relevant scientific questions and provides additional analyses of the existing clinical data.

CHMP concludes that the evidence does not support the indication as proposed and recommends the corresponding regulatory outcome.

The example illustrates an important point: Article 29(4) is not inherently a safety procedure. The same legal mechanism can resolve a qualifying disagreement concerning efficacy.

84. Practical Worked Example: Safety Disagreement

Consider a DCP in which the RMS considers the benefit-risk balance acceptable but a CMS identifies a serious safety concern and considers that the available evidence raises a potential serious risk to public health.

The CMS objection is discussed through CMDh. The Member States cannot reach agreement.

The RMS refers the matter to EMA.

CHMP assesses the safety evidence, including the clinical data and relevant post-authorisation information available to the committee. The applicant provides the requested analyses and responds to the CHMP questions.

CHMP concludes that additional restrictions are required to ensure safe use. The final regulatory outcome results in changes to the product information and associated national implementation.

For pharmacovigilance, the important consequence is not merely the amended wording. The organisation must determine what the new regulatory conclusion means for its ongoing safety surveillance and risk-management activities.

85. Practical Worked Example: Quality Disagreement

Consider an MRP or DCP in which the RMS concludes that the quality dossier supports the proposed product, while a CMS identifies a quality issue that it considers sufficiently significant to constitute a potential serious risk to public health.

The disagreement is discussed within CMDh but remains unresolved.

The matter is referred under Article 29(4), and CHMP assesses the quality evidence relevant to the referred issue.

The applicant provides additional clarification and supporting evidence. The committee's conclusion determines the regulatory consequence.

This example demonstrates why the term "Article 29 pharmacovigilance referral" is misleading. The same referral mechanism can arise from quality, efficacy, safety or product-information disagreements.

86. What Article 29(4) Does Not Mean

Article 29(4) does not mean:

that EMA has independently initiated a safety investigation;
that PRAC has necessarily assessed the issue;
that a validated pharmacovigilance signal necessarily exists;
that the medicinal product will necessarily lose its authorisation;
that every MRP/DCP disagreement reaches CHMP;
that the CHMP opinion is itself the Commission decision;
that the procedure concerns only adverse reactions;
that the referral replaces the ordinary MRP/DCP assessment.

These negative definitions are useful because many errors in regulatory interpretation arise from importing features of one EU referral procedure into another.

87. Regulatory Interpretation Principles

A reliable interpretation of an Article 29(4) procedure follows several principles.

Start with the legal trigger

Identify the statutory provision that created the procedure before analysing the scientific topic.

Reconstruct the chronology

Determine what happened in the RMS assessment, the CMS review and the CMDh process before interpreting the CHMP assessment.

Separate evidence from conclusion

Distinguish the underlying scientific evidence from the regulatory conclusion drawn from it.

Separate opinion from decision

Identify whether a document is an RMS position, CMDh position, CHMP opinion or Commission decision.

Read the scope carefully

Establish which medicinal products, strengths, pharmaceutical forms and Member States are covered.

Follow the final decision into implementation

The regulatory analysis is incomplete until the consequences of the decision have been identified and implemented.

88. Key Distinctions

The most important distinctions can be summarised as follows:

Question	Article 29(4) answer
Where does it originate?	MRP/DCP disagreement
What makes it eligible for referral?	Unresolved disagreement on potential serious risk to public health grounds
Who coordinates before referral?	CMDh
Who formally refers?	RMS
Where is it assessed at Union level?	EMA/CHMP framework
Is it necessarily pharmacovigilance?	No
Can it concern efficacy?	Yes
Can it concern quality?	Yes
Can it concern safety?	Yes
Is CHMP opinion the final legal act?	No
Who adopts the binding Union decision?	European Commission
What happens afterwards?	National implementation for the affected national authorisations

This table provides the shortest reliable mental model for distinguishing Article 29(4) from the other EU referral mechanisms.

89. Practical Checklist for Regulatory and PV Functions

When an Article 29(4) procedure is identified, the following questions provide a practical starting point:

Regulatory

What MRP or DCP generated the disagreement?
Who is the RMS?
Which CMS raised the concern?
What exactly is the disputed issue?
Is the stated basis a potential serious risk to public health?
What happened during CMDh?
What is the formal referral date?
What questions has CHMP asked?
What are the applicable procedural deadlines?
Has re-examination been requested?
What is the final CHMP opinion?
What is the Commission decision?
What national implementation is required?

Pharmacovigilance

Does the issue affect the safety profile?
Is there an existing signal or identified/potential risk?
Does the outcome alter the benefit-risk assessment?
Are safety processes or surveillance activities affected?
Is an RMP assessment or update required?
Are PSUR consequences relevant?
Does the PSMF require updating?
Does the QPPV have sufficient visibility of the outcome?

Governance

Is ownership clear?
Are regulatory and PV responsibilities defined?
Are key decisions documented?
Can the evidence supporting the company's position be retrieved?
Can the implementation of the final decision be demonstrated?

90. Conclusion

Article 29(4) is a specific mechanism for resolving an unresolved disagreement arising during a mutual recognition or decentralised procedure where the disagreement concerns a potential serious risk to public health.

Its significance lies in the transition from national coordination to Union-level assessment.

The procedure begins with the RMS and CMSs operating within the MRP or DCP. A qualifying disagreement is considered through CMDh. If agreement cannot be reached, the RMS refers the matter to EMA, where CHMP assesses the referred questions and adopts an opinion. Where re-examination is requested and accepted, the committee reassesses the challenged aspects before adopting its final opinion. The matter then proceeds to the European Commission for the binding Union decision, followed by implementation in the affected national authorisations.

For pharmacovigilance professionals, the central lesson is that regulatory subject matter should not be confused with regulatory legal basis. A referral may concern safety without being a pharmacovigilance referral. The correct interpretation begins with the procedural origin and statutory trigger.

For the QPPV, the practical importance is the interface between the regulatory conclusion and the pharmacovigilance system. Where the outcome changes the understanding of a risk or the conditions under which the medicinal product is used, the organisation must determine what that conclusion means for ongoing safety surveillance, risk management, governance and documentation.

For regulatory professionals, the most reliable approach is chronological and document-based: establish the original disagreement, follow its treatment through CMDh, identify the precise matters referred to CHMP, distinguish the committee opinion from the Commission decision, and trace the final decision into national implementation.

That approach turns an Article 29(4) referral from a collection of procedural documents into an intelligible regulatory history.

References

European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. In particular Articles 29, 32, 33 and 34.
European Medicines Agency. Questions and answers on Article 29(4) referral procedures for human medicines. Current procedural guidance.
European Medicines Agency. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh). Information and procedural guidance concerning MRP and DCP.
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Committee responsibilities and referral procedures.
European Commission. Notice and guidance concerning the definition of a potential serious risk to public health in the context of Article 29(1) of Directive 2001/83/EC.
European Commission. Rules and procedures applicable to the Union procedures for medicinal products for human use.

Regulatory Note

This article is intended as a regulatory and educational reference. It describes the EU legal and procedural framework at the time of review and should not be treated as legal advice or as a substitute for the current text of applicable legislation, EMA procedural guidance, CMDh guidance or the documents issued for an individual referral.

EU medicines legislation and procedural guidance are amended periodically. The applicable legal text, EMA and CMDh guidance, referral-specific documentation and the relevant Commission decision should therefore be checked whenever a live regulatory procedure is being assessed.

Where an individual referral is being managed, the procedure-specific EMA timetable and communications take precedence over generic descriptions in this article.